219 studies found for:    PD-1
Show Display Options
Rank Status Study
21 Recruiting Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Nivolumab
22 Active, not recruiting Phase I Biomarker Study (BMS-936558)
Condition: Renal Cell Carcinoma
Intervention: Drug: BMS-936558 (Anti-PD-1)
23 Recruiting Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Condition: Melanoma
Interventions: Drug: MK-3475;   Drug: Peginterferon alfa-2b
24 Active, not recruiting PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Condition: Renal Cell Carcinoma
Interventions: Drug: CT-011;   Biological: DC/RCC fusion vaccine
25 Recruiting Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
Condition: Melanoma
Interventions: Biological: 6MHP;   Drug: Pembrolizumab
26 Recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Conditions: Acute Myelogenous Leukemia;   AML
Interventions: Biological: DC AML Vaccine;   Drug: CT-011
27 Active, not recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: CT-011;   Biological: Dendritic Cell Fusion Vaccine
28 Recruiting Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
Condition: Non-small Cell Lung Cancer Starting Anti-PD1/PDL1 Therapy
Intervention: Radiation: [18F]fluoroglucose(FDG)
29 Recruiting Oligomeric Alpha-synuclein in Multiple System Atrophy
Condition: Multiple System Atrophy (MSA)
Intervention:
30 Suspended Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
31 Not yet recruiting Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
Condition: Recurrent Respiratory Papillomatosis
Intervention: Drug: Pembrolizumab
32 Withdrawn Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
Condition: Metastatic Melanoma
Interventions: Drug: Nivolumab;   Drug: Trametinib;   Drug: Dabrafenib
33 Recruiting Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Conditions: Advanced Cancer;   Advanced Malignancies
Interventions: Drug: REGN2810;   Radiation: Hypofractionated radiotherapy;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Carboplatin;   Drug: GM-CSF
34 Not yet recruiting Phase 1 Study of IMP321 Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma
Interventions: Drug: IMP321;   Drug: Pembrolizumab
35 Recruiting A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Conditions: Non-small Cell Lung Cancer;   Melanoma;   Malignant Melanoma of Head and Neck;   Ovarian Carcinoma;   Colon Cancer
Intervention: Drug: Combination of varlilumab and nivolumab
36 Not yet recruiting Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
Conditions: Advanced Non-small Cell Lung Cancer;   Metastatic Non-small Cell Lung Cancer;   Lung Neoplasms
Interventions: Biological: Vigil™;   Drug: Nivolumab
37 Withdrawn CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Conditions: Breast Cancer;   Colon Cancer;   Pancreatic Cancer;   Sarcoma;   Ovarian Cancer
Interventions: Biological: p53: 264-272 peptide;   Drug: CT-011
38 Recruiting Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
Conditions: Urothelial Cancer;   Bladder Cancer
Interventions: Other: Placebo;   Drug: Pembrolizumab
39 Recruiting The Clinical Relevance of Immune Cells and CTC in HNSCC Patients
Conditions: Recurrence;   Metastasis;   Death
Intervention:
40 Active, not recruiting Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain
Condition: Parkinson's Disease
Intervention: Drug: Glycerol Phenylbutyrate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years